Australian (ASX) Stock Market Forum

BMT - Beamtree Holdings

Jump to new
System

System

Joined
27 June 2010
Posts
4,202
Reactions
328
PKS is an Australian healthcare technology company that provides a proprietary subscription based Clinical Decision Support system (CDS) called "RippleDown". RippleDown automates the human decision-making process within healthcare organisations based on rules set within the organisation by domain experts.

PKS' customers include laboratories, hospitals and other healthcare organisations and RippleDown was developed to address major issues within these organisations, including:
  • the increased financial pressures that are being faced;
  • a continual rise in patient volumes;
  • rising expectations for patient outcomes; and
  • succession risk from changes in personnel.
The RippleDown CDS software consists of two separate products:
  • RippleDown Expert that has applications for the clinical side of a healthcare organisation's operations; and
  • RippleDown Auditor that has applications for the financial side of a healthcare organisation's operations.
PKS distributes its products via two key channels, being direct sales using its own sales resources and through three global channel partners, being Abbott, Philips and Thermo Fisher. Sales through channel partners represented approximately 30% of total revenue in FY2018, which has grown from 10% of total revenue in FY2016.

It is anticipated that PKS will list on the ASX during June 2019.

https://pks.com.au
 
IPO at 20c, got above that for a while but in the dumps since then and only around 15-16c

Direct sales or a Channel Partner,the company doesn't seem to be picking up many licenses. Maybe aiming for pathology first and moving into the larger (usually colocated) hospital businesses will work but, so far, very disappointing. Like most of these efforts (ALC another).
 
Just some musings on the chart below as my latest phase in charting has caught some patterns here that seem to have played out well.

Will it recover and BO for a trade ( not for me as I have been burnt to many times at this end of the cesspool ) ??

upload_2020-1-27_18-0-54.png
 
Just updating the thread and SP has been bouncing between 14.5 and 15.5 cents over the last few days, which isn't a bad sign.

The down trend appears to have slowed or completed and now the pause before the recover ??? interesting to watch
 
PKS has acquired 100% of Pavilion Health Australia Pty Ltd in an all scrip transaction.

• Pavilion Health is an Australian cloud-based software company, operating under a Software as a Service (SaaS) model, providing audit and risk applications and consulting services to hospitals and governing health bodies globally.

• The strategic benefits and synergies for this acquisition include:
- Scale: the resulting combined entity increases revenue by c 113% (FY19A), diversifies customer base with a c 58% growth to 190+ customers;
- Customers: strong cross and upselling product potential between complementary customer bases;
- Technology: combined delivery of an enhanced product roadmap into hospitals and pathology sectors whilst facilitating trends of digitisation and use of analytics to improve efficacy and efficiency in healthcare; and
- Management: bolster expertise of executive management with the addition of a COO, CTO and CCO from Pavilion.
• Pavilion Health audited sales for FY2019 were $4.37 million and will double the sales for PKS. Operational EBITDA for FY2019 was $ 1.66 million.

• The acquisition is on an all scrip, cash free and debt free basis with Pavilion Health shareholders being issued 65.2 million new PKS shares, which equates to 35% of the company post acquisition. The issue of these shares is subject to PKS shareholder approval at an Extraordinary General Meeting.
• At the share price of $0.13 as of 17th April 2020, it values the acquisition at 1.9x FY19 revenue and 5.1x FY19 Operational EBITDA

- punters like it (now 16c), as the new entity is almost double in size, and "is consistent with PKS’ growth strategies to acquire complimentary healthcare technology companies and expand beyond pathology."

 
Someone seems happy to keep acquiring PKS scrip (and some tired, stale holders happy to let it go :)).

Up from 16c to 22c in the last few days on a bit of volume.
 
As PKS Holdings Ltd has only existed in its current form for one month in FY 2019 (after listing on the ASX) and acquired Pavilion Health in June 2020, the best way to present and analyse how the business is progressing is by comparing the 2019 proforma results to the 2020 reported results and the proforma of the group business for 2020.
• Pro forma Recurring revenue of $5.56 million (total pro forma revenue of $7.46 million).
• Pro forma Recurring revenue 75% of total revenue.
• Pro forma Operational EBITDA of $2.98 million. This represents a 40% margin.
• Net cash of $4.2 million and no debt.
• Positive cash flow generation in FY20 of $1.04 million.

The market where PKS is operating is large and growing.
..... the execution of its new growth plans has commenced.
...... the addition of Pavilion Health to the company has made PKS' future secure.
• This acquisition doubled the size of PKS and increased its customer base to over 170.

The outlook for 2021:
• Target revenue growth in excess of 20% through
..... Significant enhancements in the product portfolio
..... Cross sell products between PKS and Pavilion
• Continued high recurring revenue (+70%)
• Maintain high Operating EBITDA margin (≅40%)
• Maintain positive operational cashflow generation
• Execute synergistic acquisitive growth

upload_2020-8-28_16-11-33.png
 
new appointment of Tim Kelsey as the new Chief Executive Officer to lead the next phase of growth. The Company’s current Managing Director, Ron van der Pluijm will support Tim throughout the transition and continue in his role as non-executive Director.

Tim Kelsey is an internationally regarded leader in data analytics and digital transformation. Has specialised in online data products to support health providers around the world analyse their clinical and economic performance.

- market likes it; up 10%
 
Dona Ferentes said:
new appointment of Tim Kelsey as the new Chief Executive Officer to lead the next phase of growth. Tim is an internationally regarded leader in data analytics and digital transformation
Click to expand...
maybe took a while for word to get out? Ann. on morning of 6th...
1602222299868.png
 
hit a high of 35c today

• PKS signs its largest ever single agreement for a USD$1.65 million (~AUD$2.25 million) strategic consultancy engagement to audit health data in public hospitals in the Kingdom of Saudi Arabia
• The value of this agreement will be a material driver of revenue and earnings for PKS in FY21 and FY22 and is equivalent to approximately 30% of total PKS FY20 pro-forma revenue
• The engagement is expected to run over a 12-month period and will involve analysing the data of more than 270 hospitals and generate similar or better gross margins as per other data audit contracts it has conducted in the past
• PKS’ core software products PICQ® and RISQ™ will be integral in the delivery of the health data audit consulting services
• Following the completion of these audits, customers often license PKS software products such as PICQ® and RISQ™ on an ongoing basis which drives ongoing software recurring revenues { Pavilion Health, a wholly owned subsidiary of PKS, has previously completed similar contracts with the Irish and Singapore Governments covering the data audits of a large number of hospitals }

- get paid to show that they need your product?

(Hold)
 
Candour


arichlife.com.au

3 Embarrassing Investing Mistakes I Made In 2020 - A Rich Life

It only took 6 weeks for one stock to incinerate 54% of my capital invested...
arichlife.com.au arichlife.com.au

First up, I cover PKS Holdings (ASX: PKS). Now, this one is the most embarrassing because my friend actually covered the stock in detail (after I had sold).
According to Sharesight, my overall loss with this stock is ~26.4%. However, my recollection of a 50% loss is not far off. When I drill into the details, my highest purchase was at 19c per share in November 2019, while my lowest sell was at 10.5 cents per share in March 2020.
I may have been a bit harsh on myself in my reflections though given the company is now trading at 32c per share, whoever bought my shares in March is sitting on a ~200% gain in less than a year, so I was definitely the patsy at the poker table...
Click to expand...
 
PKS receives $12 million in firm commitments to drive growth strategy

Highlights

● PKS receives firm commitments to raise $12 million through strongly supported placement
● New institutions welcomed to the Company along with continued support from existing investors
● Funds raised will be used to accelerate research & product development, sales & marketing activities, data science & informatics work as well as automated coding and enhance global sales support
● Share Purchase Plan to eligible, existing investors to raise an additional $1 million to follow

Directors Participating
Non-Executive Directors’ Andrew Gray and Stephen Borness received an allocation in the Placement. New Shares allocated to these parties, totalling 6,342,857 will only be issued subject to receiving shareholder approval at an Extraordinary General Meeting. Assuming approval, individual holdings will be as follows:
• Andrew Gray, via his nominee will increase by $1.75m. This increase will add 5m shares for a total holding of 6.25m shares (approximately 2.9% of total issued shares of the Company)
• Stephen Borness, via his nominee will Increase by $470,000. This increase will add 1,342,857 shares for a total holding of approximately 11.3m shares, and becoming a substantial holder

Indirectly, Investment funds associated with Chairman Mike Hill and Non-Executive Director Brad Lancken also participated in the placement as follows:
• Mike Hill: The Bombora Special Investment Growth Fund increased its stake by approximately $1.75m – Substantial Notice has been issued to the ASX today; and
• Brad Lancken: The Inspire Australian Equities Fund by approximately $200,000.

The SPP closes tomorrow. Priced at 35c, trading has been pretty low-key since the placement, and barely holding its head above the allocation price. Will PKS be one of those that powers on up, when the dust has settled, or is this as good as it gets?

Hold, and/ but undecided if it is worth a further punt.

1616040066274.png
 
● PKS receives firm commitments to raise $12 million through strongly supported placement
● Share Purchase Plan to eligible, existing investors to raise an additional $1 million to follow
Click to expand...
put in for $7K or 20,000 but got 11,000 = $3,850.
 
As the close of the financial year approaches, PKS has seen a near complete contract renewal rate – retaining 99% of customers. This puts the company ahead of expectations of recurrent revenue exceeding 70% of total operating revenue.
Click to expand...
Also picking up new contracts: some Ramsay hospitals and also Mater Qld (where one leads, the rest would follow?!)

... pipeline development moving into the next financial year includes a recent agreement with the Ministry of Health in Singapore to initiate a trial of PICQ® and RISQTM ahead of potential national rollout in all public and private hospitals in Singapore.

.... PKS's largest international advisory engagement in the Kingdom of Saudi Arabia (TCV $2m) is delivering on agreed milestones, timing and cost budgets... The current project is planned to finish in November 2021 with significant current activity in building the sales pipeline for the coming years in this important region.


(HOLD - seem to be the only one interested)
 
Dona Ferentes said:
Also picking up new contracts: some Ramsay hospitals and also Mater Qld (where one leads, the rest would follow?!)

... pipeline development moving into the next financial year includes a recent agreement with the Ministry of Health in Singapore to initiate a trial of PICQ® and RISQTM ahead of potential national rollout in all public and private hospitals in Singapore.

.... PKS's largest international advisory engagement in the Kingdom of Saudi Arabia (TCV $2m) is delivering on agreed milestones, timing and cost budgets... The current project is planned to finish in November 2021 with significant current activity in building the sales pipeline for the coming years in this important region.


(HOLD - seem to be the only one interested)
Click to expand...
Not the only one interested, it just needs to get to 44 before I become real interested.
 
The Company proposes to change its name from PKS Holdings Limited to “Beamtree Holdings Limited” which more suitably reflects the proposed future operations of the Company and its global presence.

And a ticker change to BMT

The brand change will futureproof and reinvigorate the company’s persona as we implement our growth strategy to expand existing and new products and services. It emphasizes our long term commitment to innovation with the customers and communities we serve both in Australia and around the world. ‘Beamtree’ is a global enterprise that supports the clinical, economic and human imperative of best value healthcare.

Definitional meaning -
1. the Beamtree is a relative of the pear tree.
2. A physical phenomenon created when an electron beam travelling near the speed of light is focused on a plastic surface creating river-like patterns.
3. The name for an approach to the visualisation of large hierarchical datasets.
 

Similar threads

TacoTed
TTZ - Total Telcom Inc.
Replies
2
Views
2K
TacoTed
TacoTed
System
NXS - Next Science
2
Replies
25
Views
6K
Dona Ferentes
Dona Ferentes
Dividend
Ultimate Acronym List (UAL)
Replies
0
Views
5K
Dividend
Dividend
Top